Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.

Clinical trial NCT07684898 · RECRUITING

Trial details

NCT number: NCT07684898
Sponsor: Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Severe Hemophilia A

Start date: 2026-06-12
Primary completion: 2027-03-09
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.